Clinical Trial Update: Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial

View source ↗

Summary

Prospective cohort in Rouen evaluating six cycles of neoadjuvant modified FOLFIRINOX for potentially resectable pancreatic ductal adenocarcinoma as a candidate …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Resectable Pancreatic Duct Adenocarcinoma | Status: NOT_YET_RECRUITING